适应性辩证行为疗法治疗双相情绪不稳定的可行性与成本效果研究
本研究为II期可行性研究,旨在评估ThrIVe-B方案(针对双相谱系障碍发作间期情绪波动的辩证行为疗法干预)的可行性与可接受性。计划招募48名受试者随机1:1分配至常规治疗组或ThrIVe-B联合常规治疗组,随访至15个月,主要终点为9个月。将评估招募保留率、量表完成率及参与者反馈,并设定进展至确定性试验的可行性标准。
要点
- 针对双相谱系障碍发作间期频繁情绪波动,目前无循证心理干预。
- ThrIVe-B为辩证行为疗法改编方案,计划招募48例随机分组。
- 主要终点为9个月,可行性标准包括随访数据≥60%及治疗完成率≥60%。
核心结论
- 本研究为II期可行性评估,旨在为未来确定性试验提供依据,尚未报告临床或成本效果结论。
研究设计与样本
- 随机1:1平行对照可行性研究,计划招募48例符合双相谱系障碍诊断且报告发作间期频繁情绪波动的个体。
- 通过初级和二级保健服务及自我转诊招募,随访点为基线后3、6、9和15个月,9个月为主要终点。
主要发现
- 原文未报告研究结果,仅描述将评估招募率、保留率、量表完成率及参与者反馈。
关键数值与推荐
- 进展至确定性试验需满足:试验参与不对参与者造成严重负面后果。
- 进展至确定性试验需满足:对试验程序可接受性和可行性的严重关切可在确定性试验前纠正。
- 进展至确定性试验需满足:至少60%的参与者在9个月时获得随访数据。
- 进展至确定性试验需满足:ThrIVe-B组至少60%的患者完成治疗。
临床怎么用
- 目前尚无循证心理干预针对双相谱系障碍发作间期情绪波动,本研究为未来干预试验提供可行性框架。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In bipolar spectrum disorder, some individuals experience ongoing, frequent fluctuations in mood outside of affective episodes. There are currently no evidence-based psychological interventions designed to address this. This feasibility study is a phase II evaluation of a dialectical behavioural therapy-informed approach (Therapy for Inter-episode mood Variability in Bipolar [ThrIVe-B]). It seeks to examine the feasibility and acceptability of a future definitive trial evaluating the clinical and cost effectiveness of the ThrIVe-B programme. METHODS/DESIGN: Patients will be randomised 1:1 to either treatment as usual only (control arm) or the ThrIVe-B intervention plus treatment as usual (intervention arm). Follow-up points will be at 3, 6, 9 and 15 months after baseline, with 9 months as the primary end point for the candidate primary outcome measures. We aim to recruit 48 individuals meeting diagnostic criteria for a bipolar spectrum disorder and reporting frequent mood swings outside of acute episodes, through primary and secondary care services and self-referral. To evaluate feasibility and acceptability, we will examine recruitment and retention rates, completion rates for study measures and feedback from participants on their experience of study participation and therapy. DISCUSSION: Proceeding to a definitive trial will be indicated if the following criteria are met: (1) trial participation does not lead to serious negative consequences for our participants; (2) any serious concerns about the acceptability and feasibility of the trial procedures can be rectified prior to a definitive trial; (3) follow-up data at 9 months are available for at least 60% of participants; (4) at least 60% of patients in the ThrIVe-B arm complete treatment. TRIAL REGISTRATION: ISRCTN, ISRCTN54234300 . Registered on 20 July 2017.
引用
- Wright K, Dodd A, Warren FC, et al. The clinical and cost effectiveness of adapted dialectical behaviour therapy (DBT) for bipolar mood instability in primary care (ThrIVe-B programme): a feasibility study. Trials. 2018. PMID: 30326960. doi:10.1186/s13063-018-2926-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。